04:44 PM EDT, 04/09/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) , a clinical-stage immunotherapy company focused on the development of Superkines that saw its shares drop near 12% today, after trade Tuesday said it presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist, in patients with advanced solid tumors, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held on April 9, 2024.

This comes after the company earlier on Tuesday said new preclinical data on MDNA113, its T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, was presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9.

The company's shares closed down C$0.20 to C$1.50 on the Toronto Stock Exchange.